Posted by Michael Wonder on 05 May 2020
Acceleron receives PRIME Designation from EMA for sotatercept in pulmonary arterial hypertension
4 May 2020 - PRIME designation comes just three weeks after US FDA granted sotatercept breakthrough therapy designation.
Acceleron Pharma today announced that the EMA has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.
Sotatercept is the first therapeutic to receive PRIME designation in pulmonary arterial hypertension since the EMA established the program in 2016.
